

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HIS

衍生集團(國際)控股有限公司

Hin Sang Group (International) Holding Co. Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6893)

VOLUNTARY ANNOUNCEMENT

(i) COMPLETION OF CONSTRUCTION OF THE PRODUCTION PLANT AND (ii) THE GRANT OF THE LEGAL CERTIFICATE OF FOOD AND FOOD ADDITIVE PRODUCTION LICENCE

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Hin Sang Group (International) Holding Co. Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company (the “**Shareholders**”) and potential investors informed of the latest business development of the Group.

Reference is made to the announcements of the Company dated 21 June 2017, 22 February 2019 and 28 November 2019 (the “**Announcements**”) in relation to, among others, the development and construction of a production plant of the Group for the manufacturing of health supplements targeting the infants and children market (the “**Production Plant**”) situated in the Yunfu Health Medical Industrial Park* (雲浮市健康醫藥產業園), with a total site area of approximately 100 mu.

The Board is pleased to inform the Shareholders and potential investors that the construction (together with the relevant inspection) of the Production Plant has been completed on 30 April 2020. On 8 May 2020, Hin Sang Health and Medical (Guangdong) Company Limited* (衍生健康醫藥(廣東)有限公司), a wholly-owned subsidiary of the Company, has obtained the legal certificate of food and food additive production licence (the “**Licence**”) from the relevant PRC authority. The successful obtaining of the Licence indicates that all relevant aspects of the Production Plant, including site environment, production and process flow, equipment layout, storage site condition and personnel health management, conformed with the relevant inspection standards and were approved. The Production Plant is expected to commence production of the Group’s own brand health supplement products in June 2020.

As previously disclosed in the Announcements, the Production Plant is expected to benefit the Group in facilitating the growing scale of its business, increasing production volume and efficiency, as well as attaining more stringent quality control. The Production Plant is equipped with advanced production and processing equipment and has multiple production lines which enable automatic production and packaging of the Group's own brand health supplement products. Going forward, with the Production Plant in operation, it is expected that the Group would be able to provide research and development, processing, product inspection, brand management and sales and promotion services.

Apart from producing the Group's own brand health supplement products, the Production Plant may also provide services to other Original Equipment Manufacturers ("OEM") and Original Design Manufacturers ("ODM") by producing high-quality products that meet the Good Manufacturing Practice (GMP) requirements. It is expected that the Production Plant would be able to provide services to OEMs and ODMs mainly in the food and beverages industry.

The Board wishes to note that no forecast or prediction of the profits of the Group has been made in relation to the completion of the construction of the Production Plant and/or its expected commencement of production.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

** For illustration purpose only.*

By Order of the Board
Hin Sang Group (International) Holding Co. Ltd.
Pang Siu Hin
Chairman

Hong Kong, 13 May 2020

As at the date of this announcement, the executive Directors are Mr. Pang Siu Hin and Ms. Kwan Lai Man, the non-executive Directors are Ms. Wong Wai Ling and Mr. Yuen Chi Ping, and the independent non-executive Directors are Mr. Lau Chi Kit, Mr. Lee Luk Shiu and Dr. Tang Sing Hing, Kenny.